Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characterization of Anti-Canine PD-1 Antibodies.

Cells·2026

Same author

Developing Nanotechnology for Intratumoral Immunotherapy.

Molecular pharmaceutics·2026

Same author

EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy.

JCI insight·2026

Same author

Bioprinting collagenase-responsive hydrogel for controlled release of cowpea mosaic virus immunotherapy.

Biofabrication·2026

Same author

Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Cell death and differentiation·2025

Same author

Atomistic TCR-ligand interactions instruct memory T-cell differentiation.

bioRxiv : the preprint server for biology·2025

Same journal

Engineering Functional Graphenic Materials for Bone Repair.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Advances in Engineered Virus-Like Particles for Applications in Nanomedicine.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Lipid- and Polymer-Based Nanoscale Delivery of Anti-Aging Phytochemicals.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Nano-Enabled Toxicity of Pharmaceutical Excipients.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Advances in Self-Assembly Artificial Chaperone for Protein Folding Regulation.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 26, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Stimulating antitumor immunity with nanoparticles.

Mee Rie Sheen¹, Patrick H Lizotte, Seiko Toraya-Brown

¹Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.

Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology

|July 30, 2014

Summary

This summary is machine-generated.

Nanoparticles (NPs) show promise in cancer immunotherapy by reprogramming immune cells to reverse tumor-induced immunosuppression. This approach enhances antitumor immune responses for more effective cancer treatment.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Apr 26, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

Area of Science:

Oncology
Immunology
Nanotechnology

Background:

Immunotherapy is a key cancer treatment strategy, but tumors often evade immune detection through immunosuppression.
Tumor cells orchestrate immunosuppression, hindering effective antitumor immune responses.
Nanoparticles (NPs) offer a promising platform for modulating immune cells involved in cancer progression.

Purpose of the Study:

To review NP-based strategies for reversing tumor-mediated immunosuppression.
To explore how NPs can stimulate innate and adaptive immune systems against tumors.
To highlight the potential of engineered NPs in cancer immunotherapy.

Main Methods:

Reviewing various NP-based cancer therapy approaches.
Analyzing NP engineering with therapeutic payloads (antigens, immunomodulators).
Investigating NP interactions with phagocytes to manipulate immune responses.

Main Results:

Nanoparticles can be engineered to deliver payloads that counteract tumor immunosuppression.
Phagocytes, crucial immune regulators, actively uptake NPs, allowing targeted manipulation.
Engineered NPs can stimulate both innate and adaptive immune systems.

Conclusions:

Nanoparticle-based therapies hold significant potential for reversing tumor immunosuppression.
Targeting phagocytes with NPs can reprogram the tumor microenvironment for effective antitumor immunity.
Further development of NP payloads will expand their application in cancer immunotherapy.